Precision Biosensor, Inc. and U.S. Nexus Dx, Inc. have signed a memorandum of understanding (MOU) to develop Point of Care Instrument and its services in the field of In-Vitro Diagnostics (IVD) on September 7, 2018.
The signing of the MOU will see to the furthermore recognition of the research and development capability of Precision Biosensor in the global market and its continuous enhancement of higher quality level products that satisfy the needs of the market.
This partnership and joint development with Nexus Dx, a company specializing in overseas diagnosis and its biomarker, will aim to continuously expand wide-range of test items as well.
Based on MOUs, both companies will continue to discuss business cooperation and the Agreement for collaboration will be signed later this year.
Nexus Dx, Inc. is a U.S. in-vitro Diagnostics equipment and reagent development/supplier recently separated from Samsung Electronics' Healthcare & Medical Equipment Business. Nexus is manufacturing its IB10 instrument, developed through investment of approximately $160 million, worldwide along with is cardiology markers and infectious disease tests as well.